Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 6, 2026

Amazon Q4 Earnings Miss Estimates, Shares Slide on $200B Capex Plan

View original at finance.yahoo.com
“Net sales of $213.4 billion rose 14% year over year, which was ahead of management's guidance of $206-$213 billion”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Plans more than 20 Amazon LEO satellite launches in 2026 and over 30 in 2027

    80% confidence

  • Net sales guidance for Q1 2026 is between $173.5 billion and $178.5 billion, representing 11% to 15% growth

    80% confidence

  • Amazon LEO commercial rollout is expected later in 2026

    80% confidence

  • Graviton is used by more than 90% of the top 1,000 AWS customers

    80% confidence

  • Operating income guidance for Q1 2026 is expected to range between $16.5 billion and $21.5 billion

    80% confidence

  • Shoppers using Rufus show 60% higher purchase completion rates

    80% confidence

  • AWS custom chips business including Trainium and Graviton now has a combined annual revenue run rate of more than $10 billion and is growing at triple-digit percentages year over year

    80% confidence

  • Amazon Bedrock is now a multibillion-dollar annualized run rate business with customer spend growing 60% quarter over quarter

    80% confidence

  • Trainium4 is expected to start delivering in 2027

    80% confidence

  • Plans to invest approximately $200 billion in capital expenditures in 2026, predominantly in AWS

    80% confidence

  • Graviton5 is up to 40% more price-performant than leading x86 processors

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Amazon Q4 Earnings Miss Estimates, Shares Slide on $200B Capex Plan — Source | Via News | ViaNews Market